The 2025 Taihu Bay Future Conference on Life and Health, hosted by the Wuxi People's Government, was held from May 16 to 18, 2025, at the Taihu International Expo Center in Wuxi. Centered on the theme "Empowering the Future of Health with Digital Intelligence," the conference brought together leading experts and industry leaders from around the world to discuss cutting-edge developments and explore collaborative opportunities in the life and health sector.

1. Invited to Attend: Focusing on Health Screening and At-Home Testing

Metanotitia was invited to participate in the “Health Screening and At-Home Testing Forum” during the conference, which was successfully held on May 17 at the Wuxi Taihu International Expo Center. The forum provided a valuable platform for in-depth exchange and collaboration among industry peers. Mr. Chen Enpin, Deputy Director of Wuxi Health Commission and Director of the Wuxi Center for Disease Control and Prevention, delivered the opening remarks. Centered on the theme of “At-Home Health Monitoring and Early Screening Technologies,” the forum featured a series of keynote speeches and panel discussions, aiming to promote the integration of screening technologies into community and household settings, and to enhance the efficiency of early warning and intervention.

2. Thematic Report: AI + Metabolomics Technology Empowering Precision Medicine and Health Management

Research and Development Status

• Metanotitia leverages its independently developed ProfMet metabolomics research platform, pioneering applications in early screening and diagnosis of multiple malignant tumors as well as digital precision health management. Guided by a “data-algorithm-scenario” strategic framework, the company is advancing the research, development, and commercialization of various in vitro diagnostic (IVD) products and one-stop health management services.
• The company has completed the development of metabolic models and biomarker algorithms for several high-risk cancers including lung, gastric, and colorectal cancers. The phased R&D outcomes of the MCTarg® series have been presented at top industry conferences such as the American Association for Cancer Research (AACR) and the European Association for Cancer Research (EACR).
• Through the establishment of a “10,000-Person Health Cohort,” Metanotitia’s Smart Metabolism® series product—Metabolic Physiological Age Assessment—has gained recognition and support from industry experts. This product has entered into cooperation agreements with B2B clients for authorized commercial promotion and application.

Future Plans

• The next phase aims to expand clinical collaborations nationwide, striving to complete model development and validation for 15 cancer types by the end of 2025, with a sample size exceeding 50,000 cases, to further enhance the sensitivity and specificity of pan-cancer screening products.
• For specific cancer types, the company will advance clinical trials and IVD registration applications for single-cancer auxiliary diagnostic products, improving product readiness and deepening cooperation with top-tier hospitals and specialty medical institutions.
• The company also plans to integrate multimodal data fusion and AI deep learning technologies to optimize health management algorithms, enrich the product portfolio, and realize an integrated solution covering “screening—diagnosis—intervention—prediction.”

At the forum, Dr. Liu Li, R&D Project Director, provided a detailed presentation on the above progress and plans. She engaged in in-depth discussions with industry experts on key issues such as data standardization, algorithm iteration, and sample management, bringing new insights and inspiration to the field.

3. In-Depth Exchanges: Expanding Collaboration Opportunities
During the event, the Metanotitia team engaged in a series of closed-door discussions with technical experts, medical institutions, and testing service providers from various fields. The conversations focused on topics such as "at-home sampling technology," "development of non-invasive diagnostic reagents," and "remote monitoring solutions." Many participants expressed strong interest in Metanotitia’s technology platform and product progress, and preliminary discussions were held regarding potential collaboration models in community healthcare, corporate health management, and personalized precision health management scenarios.

4. Strategic Cooperation: Joining Hands with Zaodx to Build a Healthy Ecosystem

During the forum, Metanotitia formally signed a strategic cooperation agreement with Zaodx (www.zaodx.com), China’s leading academic exchange and industry service platform for health screening. Zaodx is dedicated to promoting the concepts of “early screening, early diagnosis, and early treatment” and is committed to advancing the industrialization and standardization of health screening.

• Scope of Cooperation:
  The two parties will leverage complementary resources to establish a business partnership, jointly organizing academic and corporate exchange events both online and offline. They will co-develop training and certification systems for early screening technologies, synchronize the development of an integrated “at-home sample collection + laboratory testing” solution, and co-build a big data center for early screening to enable shared service capabilities and data resources.
• Significance of Cooperation:
  This strategic partnership will combine Zaodx’s extensive influence in academic exchange and industry services for health screening with Metanotitia’s high-throughput metabolomics testing and AI interpretation technologies. Together, they will create an integrated early screening solution based on “at-home sample collection + laboratory testing,” significantly improving screening efficiency and coverage while reducing public health risks. The collaboration will further promote the widespread adoption of the “early screening, early diagnosis, early treatment” philosophy, aligning with the national “prevention-centered” health strategy. Through multimodal data sharing and standardized management, it will provide solid technical and data support for the Healthy China initiative.
• For Metanotitia, this partnership will leverage Zaodx’s broad industry resources and academic influence to accelerate the market launch and ecosystem development of its IVD products, further strengthening the company’s leading position in precise metabolomics and enabling mutual enhancement of technology and services.

5. Looking to the Future: Empowering Public Health

Through deep engagement in this conference and the signing of the strategic partnership, Metanotitia not only demonstrated its technological strengths in metabolomics testing and AI empowerment but also laid a solid foundation for collaborative innovation with upstream and downstream partners in the industry chain. Moving forward, Metanotitia will continue to strengthen its technology development and clinical validation efforts, working together with Zaodx and more partners to explore new models of at-home screening. Together, they aim to promote the transition of health screening from laboratories into millions of households, safeguarding the health of the entire population.